-

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on January 9, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 39,169 shares of common stock and 13,895 restricted stock units (“RSUs”) to eleven new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option has an exercise price per share equal to $30.66 per share, Acadia’s closing trading price on January 9, 2024, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with Acadia through the applicable vesting dates. The RSUs will vest over four years, with 50% of the underlying shares vesting on the second anniversary of the grant date, and the balance of the underlying shares vesting in two equal annual installments measured from the second anniversary of the grant date, subject to the new employees’ continued service relationship with Acadia through the applicable vesting dates. The awards are subject to the terms and conditions of Acadia’s 2023 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only FDA-approved drug for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter.

Contacts

Media Contact:
Acadia Pharmaceuticals Inc.
Deb Kazenelson
(818) 395-3043
media@acadia-pharm.com

Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
ir@acadia-pharm.com

Acadia Pharmaceuticals Inc.
Jessica Tieszen
(858) 261-2950
ir@acadia-pharm.com

Acadia Pharmaceuticals Inc.

NASDAQ:ACAD

Release Versions

Contacts

Media Contact:
Acadia Pharmaceuticals Inc.
Deb Kazenelson
(818) 395-3043
media@acadia-pharm.com

Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
ir@acadia-pharm.com

Acadia Pharmaceuticals Inc.
Jessica Tieszen
(858) 261-2950
ir@acadia-pharm.com

More News From Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Presents Additional Phase 2 RADIANT Study Results Evaluating Remlifanserin for the Treatment of Alzheimer's Disease Psychosis at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) Conference

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today presented additional data from the Phase 2 RADIANT trial evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) during an oral presentation at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston. Building on previously announced topline results, new analyses provided further evidence of a consistent efficacy signal with once...

Acadia Pharmaceuticals Enters Exclusive Distribution Agreement with KYORIN Pharmaceutical for DAYBUE® STIX (trofinetide) in Japan

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced that it has entered into an exclusive distribution agreement with KYORIN Pharmaceutical Co., Ltd. (TSE: 4569), for the commercialization of DAYBUE® STIX (trofinetide) powder for oral solution in Japan for the treatment of Rett syndrome. Under the terms of the agreement, KYORIN will be responsible for leading the commercialization of DAYBUE STIX in Japan and the related regulatory activities on behalf of Acad...

Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today reported that oral arguments were held before the U.S. Court of Appeals for the Federal Circuit in the appeal of the U.S. District Court for the District of Delaware’s May 2025 decision upholding Acadia’s U.S. Patent No. 11,452,721 (the ‘721 patent), which covers the NUPLAZID® (pimavanserin) 34 mg capsule formulation. “We continue to believe in the strength of our position on the NUPLAZID formulation patent, on which t...
Back to Newsroom